Learn about our successful Series A raise and how we’ve got PI3Kα-mutant cancers in our crosshairs.
We are excited to announce that Totus Medicines, a Massachusetts-based biotech startup, has emerged from stealth with a $40 million Series A funding round to develop new PI3Kα inhibitors for cancer treatment.
PI3Kα is a well-established oncology drug target, but existing drugs have had limited success in patients with PI3Kα-mutant cancers. This is due to a number of factors, including the development of resistance and off-target toxicity.
Our lead candidate, TOS-358, is a novel PI3Kα inhibitor that is designed to address these limitations. TOS-358 is a highly selective covalent inhibitor of PI3Kα, meaning that it binds to PI3Kα and forms a covalent bond, which prevents PI3Kα from functioning. TOS-358 has also been shown to be effective in preclinical models of PI3Kα-mutant cancers that are resistant to existing PI3Kα inhibitors.
We are committed to developing innovative new medicines for the treatment of cancer, and we believe that TOS-358 has the potential to be a breakthrough therapy for patients with PI3Kα-mutant cancers who have limited therapeutic options.
We are planning to initiate a Phase 1 clinical trial of TOS-358 in the second half of 2024. The trial will enroll patients with PI3Kα-mutant solid tumors. The primary objectives of the trial will be to assess the safety and tolerability of TOS-358 and to identify the recommended Phase 2 dose.
We are excited to advance TOS-358 into the clinic and to bring new hope to patients with PI3Kα-mutant cancers.
Stay tuned for more updates on our progress!